1[1]Markham A,Goa KL.Valsartan:a review of its pharmacology and therap eutic use in essential hypertension.Drugs.1997,54:299-311
2[2]Sassano P,Chatelier G,Alhenc GF,et al.Antihypertensive effect of e nalapril as first-step treatment of mild and moderate uncomplicated essential hypertension evalution by two method of blood pressure measurement.Am J Med.1984,77:18-22
4[4]Black HR,Graff A,Shite D,et al.Valsartan,a new angiotensin Ⅱ anta gonist for the treatment of essential hypertension efficacy,tolerability and safety compare d to an angiotensin-converting enzyme inhibitor,lisinopril.J Hum Hypertens.1997, 11:483-489
5[5]Hall J,Marbury T,Gray J,et al.Long term safety,tolerability and ef ficacy of valsartan results from one and two years trials.J clin Res,1998,1:147-159
6[6]Fogari R,Zoppi A,Mugellini A,et al.Comparative efficacy of losarta n and vasar tan in mildto-moderate hypertension results of 24-hours ambulatory blood pressur e monitory.Curr Ther Res.1999,60:195-206
7[7]Corea L,Cardoni O,Fogari R,et al.Valsartan,a new angiotensin Ⅱ an tagonist fo r the treatment of essential hypertension:a comparative study of the efficacy an d safety against amlodipine.Clin Pharmacol Ther.1996,60:341-346
8[8]Perico N,Spormann D,Peruzzi E,et al.Efficacy and tolerabillity of valsartan c ompared with lisinopril in patients with hypertension and renal insufficiency.Cl in Drug Invest.1997,14:252-259
9[9]Brookman LJ,Rolan PE,Benjamin IS,et al.Pharmacokinetics of Valsart an i n patients with liver disease.Clin Pharmacol Ther.1997,62:272-278
10[10]Ruilope LM.Cardiovascalar and renal risks of calcium-channel bloc kers,news from the Hotstudy.Nephrol Dial Transplant.1999,14:286-287
